Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): A mechanism for methotrexate-mediated immunosuppression

Clinical and Experimental Immunology

Volumn 115, Issue 1, 1999, Pages 42-55

  Neurath, Markus F ^a,d   Hildner, K ^a   Becker, C ^a   Schlaak, J F ^a   Barbulescu, K ^a   Germann, T ^a   Schmitt, E ^a   Schirmacher, P ^a   Haralambous, S ^b   Pasparakis, M ^b   Meyer Zum Buschenfelde K H ^a   Kollias, G ^b   Marker Hermann E ^a,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Arthritis tumour; Cytokines; Methotrexate; Necrosis factor

Indexed keywords

COLLAGEN TYPE 2; CYTOKINE; GAMMA INTERFERON; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CD4-POSITIVE T-LYMPHOCYTES; COLLAGEN; CYTOKINES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-15; INTERLEUKIN-4; INTERLEUKIN-6; MACROPHAGES; MALE; METHOTREXATE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, KNOCKOUT; MICE, TRANSGENIC; SPLEEN; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032916872     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00753.x     Document Type: Article

References (42)

1. 1 Kavanaugh AF, Lipsky PE. Rheumatoid arthritis. In: Rich RR, ed. Clinical immunology. St Louis: Mosby, 1996:1093-116.
2. 2 Müller-Ladner U. Molecular and cellular interactions in rheumatoid synovium. Curr Opin Rheumatol 1996; 8:210-20.
3. 3 Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144:3347-53.
4. 4 Chen E, Keystone EC, Fish EN. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum 1993; 36:901-10.
5. 5 Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40:397-409.
6. 6 Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36:1681-90.
7. 7 Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
8. 8 Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Ann Rev Immunol 1989; 7:625-55.
9. 9 Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13:151-3.
10. 10 Strober W, Kelsall BL, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath MF. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 1997; 18:61-64.
11. 11 Neurath MF, Pettersson S, Meyer zurn Büschenfelde KH, Strober W. Local administration of antisense oligonucleotides to the p65 subunit of NF-kappaB abrogates experimental colitis in mice. Nature Med 1996; 2:998-1004.
12. 12 Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis: a predictive genetic model of arthritis. EMBO 1991; 10:4025-31.
13. 13 Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 1990; 346: 274-6.
14. 14 Brennan FM, Maini RN, Feldmann M. TNF-alpha: a pivotal role in rheumatoid arthritis. Br J Rheumatol 1993; 31:293-8.
15. 15 Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951-60.
16. 16 Weinblatt ME, Kaplen H, Germain BF et al. Methotrexate in rheumatoid arthritis: a five year prospective multicenter study. Arthritis Rheum 1994; 37:1492-8.
17. 17 Hu SK, Mitcho YL, Oronsky AL, Kerwar SS. Studies on the effect of methotrexate on macrophage function. J Rheumatol 1988; 15:206-9.
18. 18 Conolly KM, Stecher VJ, Danis E, Pruden DJ, LaBrie T. Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int J Immunopharmacol 1988; 10:717-28.
19. 19 Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989; 32:370-7.
20. 20 Meyer FA, Yaron I, Mashiah V, Yaron M. Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 1993; 20:238-42.
21. 21 Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995; 34:602-9.
22. 22 Brody M, Bohm T, Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1-beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993; 31:667-74.
23. 23 Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF-alpha-deficient mice: a critical requirement for TNF-alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397-411.
24. 24 Rook G, Thompson S, Buckley M, Elson C, Brealey R, Lambert C, White T, Rademacher T. The role of oil and agalaclosyl IgG in the induction of arthritis in rodent models. Eur J Immunol 1991; 21:1027-32.
25. 25 Germann T, Szeliga J, Hess H, Storkel S, Podlaski FJ, Gately MK, Schmitt E, Rude E. Administration of interleukin-12 in combination with type 11 collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 1995; 92:4823-7.
26. 26 Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, van den Berg WB. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249-60.
27. + T lymphocytes. J Immunol 1998; 160: 3642-7.
28. 28 McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nature Med 1997; 3:189-95.
29. 29 McInnes IB, al-Mughales J, Field M et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nature Med 1996; 2:175-82.
30. 30 Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992; 35:138-45.
31. 31 Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:88-95.
32. 32 Thomas R, Carroll GJ. Reduction of leucocyte and interleukin-1-beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36:1244-52.
33. 33 Barrera BR, Haagsma CJ, Boerbooms AM, Van Riel PL, Borm GF, Van dePutte LB, Van der Meer JW. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995; 34: 747-55.
34. 34 Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Conolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993; 5:298-304.
35. 35 Williams AS, Camilleri JP, Topley N, Williams BD. Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate. J Pharmacol Toxicol Methods 1994; 32:53-58.
36. 36 Chang DM, Weinblatt ME, Schur PH. The effects of methotrexate on interleukin-1 in patients with rheumatoid arthritis. J Rheumatol 1992; 19:1678-82.
37. 37 Williams AS, Punn YL, Amos N, Cooper AM, Williams BD. The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes. Br J Rheumatol 1995; 34: 241-5.
38. 38 Bologna C, Edno L, Anaya JM et al. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994; 37:1770-3.
39. 39 Dolhain RJEM, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AMM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1961-9.
40. 40 Constantin A, Loubet P, Lambert N, Yassine B, Abbal M, Mazieres B, Preval C, Cantagrel A. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1998; 41:48-57.
41. 41 Trentharn DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146: 857-68.
42. 42 Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joints disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-8.